Aveanna Healthcare Holdings Inc. AVAH R2K
Company Overview
Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities. The company operates through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment offers private duty nursing (PDN) services, which include in-home skilled nursing services to medically complex children and adults; nursing services in school settings in which its caregivers accompany patients to school; services to patients in its pediatric day healthcare centers; and non-clinical care, including support services and personal care services; and in-clinic and home-based therapy services, such as physical, occupational, and speech services. The HHH segment provides home health services, including in-home skilled nursing services; physical, occupational, and speech therapy services; and medical social and aide services, as well as hospice services for patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The MS segment offers enteral nutrition supplies and other products, including formulas, supplies, and pumps to adults and children delivered on a periodic or as-needed basis. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Why Investors Should Care
Return on capital employed stands at 16.2%.
Trades at a P/E of 7.7, below the sector median of 25.4.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Jan 2026 Revenue of $2.43B (+0.0% YoY); net profit $225.03M.
- Trailing 12 Months Year-on-year growth — revenue +15.9%, earnings +612.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 8.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 8.39% |
| 1 Year: | 15.90% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 612.30% |
Stock Price Performance
| 1 Year: | +129.48% |
| 6 Months: | +8.73% |
| 3 Months: | +45.26% |
| 1 Month: | +33.43% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)68.47 · Neutral
P/E of 7.72 is below the sector median of 25.41 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AVAH Aveanna Healthcare Holdings Inc. R2K | 9.34 | 7.72 | $2.03B | 0.00% | 16.15% | - | 8.39% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Apr 2021 | Jul 2021 | Oct 2021 | Apr 2022 | Jul 2022 | Oct 2022 | Apr 2023 | Jul 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 355.22M | 351.58M | 366.00M | 417.16M | 436.11M | 411.28M | 450.53M | 442.95M | 443.01M | 466.41M | 471.94M | 478.01M | 490.65M | 504.96M | - | - | 559.22M | 589.55M | 621.94M | 662.48M | 647.91M | 647.91M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 375.67M | 378.75M | 419.12M | 449.18M | 442.49M | - |
| Gross Profit | 107.54M | 106.63M | 114.13M | 131.68M | 146.59M | 139.74M | 144.83M | 145.04M | 134.58M | 144.47M | 155.25M | 147.26M | 145.85M | 158.27M | - | - | 183.56M | 210.80M | 202.82M | 213.30M | 205.43M | 205.43M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 131.65M | 127.37M | 150.42M | 140.77M | 132.99M | - |
| Operating Income | 17.87M | -51.96M | 12.88M | 28.30M | 30.29M | 18.35M | 13.78M | -456.38M | 4.79M | 17.64M | 37.49M | -76.35M | 22.87M | 37.13M | - | - | 51.91M | 83.43M | 52.41M | 72.53M | 72.44M | 69.33M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 51.78M | 87.11M | 55.67M | 78.04M | 80.82M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.69M | 36.00M | 35.13M | 31.61M | 28.19M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.15M | 44.14M | 13.42M | 39.24M | 44.98M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.96M | 17.11M | -647.00K | -139.51M | 3.32M | - |
| Net Income | 37.64M | -77.55M | -7.40M | 5.80M | 1.26M | 2.09M | 25.33M | -473.89M | 24.30M | -32.00M | 25.60M | -102.39M | -11.17M | 13.91M | - | - | 5.19M | 27.02M | 14.06M | 178.75M | 41.65M | 41.65M |
| Diluted EPS | 0.27 | -0.55 | -0.05 | 0.04 | 0.01 | 0.01 | 0.14 | -2.56 | 0.13 | -0.17 | 0.13 | -0.54 | -0.06 | 0.07 | - | - | 0.03 | 0.13 | 0.06 | 0.80 | 0.19 | 0.19 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Jan 2021 | Dec 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.38B | 1.50B | - | 1.68B | 1.79B | 1.90B | 2.02B | 2.43B | 2.43B |
| Cost of Revenue | - | - | - | - | 1.23B | 1.30B | 1.39B | 1.62B | - |
| Gross Profit | 419.25M | 454.51M | - | 542.40M | 553.23M | 595.43M | 635.54M | 810.48M | 810.48M |
| Operating Expenses | - | - | - | - | 520.06M | 481.76M | 494.26M | 550.21M | - |
| Operating Income | 38.95M | -3.49M | - | -36.11M | 33.17M | 113.67M | 141.28M | 260.28M | 256.46M |
| EBITDA | - | - | - | - | -525.06M | 39.17M | 187.38M | 269.40M | - |
| Interest Expense | - | - | - | - | 99.94M | 148.07M | 151.14M | 134.23M | - |
| Pretax Income | - | - | - | - | -663.81M | -139.00M | 5.07M | 106.95M | - |
| Tax Provision | - | - | - | - | -1.78M | -4.47M | 16.00M | -118.09M | - |
| Net Income | -76.52M | -57.05M | - | -117.04M | -662.03M | -134.52M | -10.93M | 225.03M | 225.03M |
| Diluted EPS | - | - | - | -0.69 | -3.57 | -0.71 | -0.06 | 1.05 | 1.05 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Jan 2021 | Dec 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.84B | - | 2.33B | 1.71B | 1.61B | 1.66B | 2.01B | 2.01B |
| Current Assets | - | - | - | - | - | 269.75M | 314.89M | 392.67M | 560.23M | - |
| Cash & Equivalents | - | - | 137.34M | - | 30.49M | 19.22M | 43.94M | 84.29M | 193.26M | 193.26M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | 225.63M | 245.81M | 277.66M | 316.12M | - |
| Total Liabilities | - | - | 1.58B | - | 1.70B | 1.72B | 1.74B | 1.79B | 1.82B | 1.82B |
| Current Liabilities | - | - | 260.41M | - | 344.83M | 326.50M | 354.76M | 402.17M | 424.46M | 424.46M |
| Long Term Debt | - | - | 1.16B | - | 1.23B | 1.28B | 1.28B | 1.27B | 1.29B | 1.29B |
| Total Debt | - | - | - | - | - | 1.50B | 1.50B | 1.50B | 1.51B | - |
| Total Equity | 344.99M | 270.19M | 265.03M | - | 635.82M | -4.17M | -127.44M | -122.09M | 195.19M | 194.46M |
| Shares Outstanding | - | - | - | - | - | 188.86M | 190.73M | 193.23M | 211.00M | - |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Jan 2021 | Dec 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.71M | 116.62M | - | -11.35M | -48.40M | 22.67M | 32.64M | 125.86M | 125.86M |
| Investing Cash Flow | -17.82M | -193.54M | - | -681.83M | -25.29M | -8.79M | -6.32M | -22.30M | -22.30M |
| Financing Cash Flow | 21.86M | 210.94M | - | 586.33M | 62.42M | 10.85M | 14.03M | 5.41M | 5.41M |
| Capital Expenditure | -16.64M | -15.24M | - | -15.95M | -12.01M | -8.79M | -6.32M | -7.45M | - |
| Free Cash Flow | -25.35M | 101.38M | - | -27.30M | -60.41M | 13.88M | 26.32M | 118.41M | - |
| Net Change in Cash | - | - | - | - | -11.27M | 24.73M | 40.35M | 108.97M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Jan 2021 | Dec 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 30.3% | 30.4% | - | 32.3% | 30.9% | 31.4% | 31.4% | 33.3% | 33.3% |
| Operating Margin % | 2.8% | -0.2% | - | -2.2% | 1.9% | 6.0% | 7.0% | 10.7% | 10.5% |
| Net Margin % | -5.5% | -3.8% | - | -7.0% | -37.0% | -7.1% | -0.5% | 9.2% | 9.2% |
| ROE % | -28.3% | -21.5% | - | -18.4% | 15,857.1% | 105.6% | 9.0% | 115.3% | 115.7% |
| ROCE % | - | -0.2% | - | -1.8% | 2.4% | 9.0% | 11.2% | 16.4% | 16.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Bain Capital Investors Llc | 37.47% | 81.60M | $777.25M |
| 2 | J.H. Whitney Equity Partners VII, LLC | 16.64% | 36.24M | $345.21M |
| 3 | Nut Tree Capital Management, LP | 5.93% | 12.92M | $123.09M |
| 4 | Blackrock Inc. | 2.53% | 5.50M | $52.40M |
| 5 | Summit Partners, L.P. | 2.50% | 5.45M | $51.92M |
| 6 | Vanguard Capital Management LLC | 1.83% | 3.97M | $37.86M |
| 7 | Boston Partners | 1.30% | 2.82M | $26.90M |
| 8 | Nuveen, LLC | 1.01% | 2.19M | $20.91M |
| 9 | Littlejohn & Co LLC | 1.01% | 2.20M | $20.99M |
| 10 | Braidwell LP | 1.01% | 2.20M | $20.99M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AVAH
Should Value Investors Buy Aveanna Healthcare (AVAH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to u…
Are Medical Stocks Lagging Aveanna Healthcare (AVAH) This Year?
Here is how Aveanna Healthcare (AVAH) and Align Technology (ALGN) have performed compared to their sector so far this year.
Are You Looking for a Top Momentum Pick? Why Aveanna Healthcare (AVAH) is a Great Choice
Does Aveanna Healthcare (AVAH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Despite Fast-paced Momentum, Aveanna (AVAH) Is Still a Bargain Stock
Aveanna (AVAH) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.…
Best Value Stocks to Buy in July and Hold
Exploring how investors can find highly ranked--Zacks Rank #1 (Strong Buy) or #2 (Buy)--value stocks to buy in July.
Are Investors Undervaluing Aveanna Healthcare (AVAH) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to u…
AVAH — Frequently Asked Questions
What is the current share price of Aveanna Healthcare Holdings Inc. (AVAH)?
As of 2026-07-14 21:23 PDT, Aveanna Healthcare Holdings Inc. (AVAH) trades at $9.34 on NasdaqGS. Its 52-week range is $3.74 to $10.27.
What is the market capitalisation of AVAH?
Aveanna Healthcare Holdings Inc. (AVAH) has a market capitalisation of $2.03B on NasdaqGS.
What is the P/E ratio of AVAH?
AVAH trades at a trailing price-to-earnings (P/E) ratio of 7.72. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 6.40.
Is AVAH a good stock to buy?
This page provides a data-driven analysis of Aveanna Healthcare Holdings Inc. (AVAH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.